Avoid concomitant use of tucatinib with CYP3A substrates, exactly where nominal concentration modifications may perhaps bring about critical or daily life-threatening toxicities. If unavoidable, lower CYP3A substrate dose In keeping with product labeling.bosentan will decrease the extent or impact of triazolam by affecting hepatic/intestinal enzyme